Clinical effect of vein of Marshall ethanol infusion on mitral isthmus ablation

Purpose: This study aimed to investigate the effect of Marshall ethanol infusion (VOM-Et) in the vein on mitral isthmus (MI) ablation.

Methods: Patients with persistent atrial fibrillation (AF) were grouped into vein of VOM-Et combined with radiofrequency (RF) ablation (VOM-Et-RF) and RF groups. The primary outcome was MI block immediate block rate after surgery. Stratified analysis was also performed for factors affecting the outcome measures.

Results: A total of 118 consecutive patients underwent AF ablation at Taizhou Hospital of Zhejiang Province from January 2018 to December 2021. Successful bidirectional perimitral block was achieved in 96% of patients in VOM-Et-RF (69 of 72) and in 76% of patients in the RF group (35 of 46) (P < 0.01). In the subgroup analysis, male sex, elder than 60 years, Left atrial diameter <55 mm, and AF duration <3 years were associated with the benefits of VOM-Et in AF Patients.

Conclusion: The vein of Marshall ethanol infusion for catheter ablation can improve the MI block rate. Male sex, elder age, smaller Left atrial diameter and shorter AF duration may have significant benefits for VOM-Et.

Introduction

The prevalence of atrial fibrillation (AF) is increasing with the development of an aging society. At present, for catheter ablation of persistent atrial fibrillation, substrate modifications beyond pulmonary vein isolation is still lacking in evidence for further reducing the long-term recurrence. Some researchers believe that the long-term recurrence rate of persistent AF is related to mitral valve block rate (1).

Vein of Marshall ethanol infusion (VOM-Et) has become a popular topic in recent years. The block rate of the mitral isthmus (MI) can be improved by injecting absolute ethanol into the Marshall vein. In addition, VOM-Et can also play a role in intervening the autonomic nerve and AF triggers originating from the vein of Marshall, so as to reduce the recurrence rate of catheter ablation for persistent AF. However, few study has focus on the effect of VOM-Et on mitral isthmus ablation. The present study aims to investigate the impact of VOM-Et on MI ablation, as well as potential factors associated with the effect size.

Methods

Study design

This is a single-center retrospective study which compared the effectiveness of rhythm control with two ablation strategies for persistent AF: RF alone or with Marshall vein ethanol ablation (VOM-Et-RF) (Figure 1). The protocol of the trial was reviewed and approved by the Institutional Ethics Committee. RF ablation applied a fixed anatomical ablation strategy including circumferential pulmonary vein isolation, left atrial roof, mitral isthmus, and tricuspid isthmus ablation, while additional VOM-Et was performed on the basis of aforementioned RF lesion sets in VOM-Et-RF group (Figures 2A–C).

Figure 1

Figure 1. Study flow diagram of patient entrollment.

Figure 2

Figure 2. (A) A Schematic diagram of VOM-Et (1); (B) Selective angiography of the vein of Marshall; (C) Bi-polar voltage change in the mitral isthmus and left lateral ridge before and after EIVOM; (D) Verification of a bidirectional block of the mitral isthmus.

In this study, the OTW balloon was fixedly placed at the proximal VOM. After inflation of the balloon at 6–8 atm, selective venography was performed to confirm total VOM occlusion, display the arborization of the VOM and identify collateral branches communicating with other structures. In cases, successive 5 times of ethanol was injected with 1–2 ml for each infusion and 1 min apart. At the end of VOM-Et, repeated venography was applied through the lumen of the balloon to observe tissue staining and exclude contrast extravasation into the free pericardium. After the ethanol fusion into the vein of Marshall procedure, we performed radiofrequency ablation.

Setting and participants

A total of 118 consecutive patients underwent persistent AF ablation at Taizhou Hospital of Zhejiang Province from January 2018 to December 2021. Patients were eligible if they met the following inclusion criteria: (1) age 18–85 years; and (2) symptomatic persistent AF refractory to at least1 antiarrhythmic drug (AAD). The exclusion criteria were the following: (1) thrombus on transesophageal or intracardiac echocardiography; and (2) incomplete data.

All patients were divided into two groups according to ablation strategy, which were the following: (1) radiofrequency energy (RF) alone (n = 46); and (2) radiofrequency energy combined with vein of Marshall ethanol infusion (VOM-Et-RF) (n = 72).

Variables

Patient anthropometric and procedural parameters were collected to analyze any significant association with mitral isthmus block (Figure 2D).

Measurement

Clinical assessments were performed at baseline and after the initial ablation treatment under sinus rhythm, bidirectional block of MI was determined by differential pacing techniques (Figure 2).

Quantitative variables

The correlation between MI block rate and alcohol ablation with sex, age, duration of atrial fibrillation, left atrial size, diabetes, hypertension, smoking, and alcohol consumption, was examined by correlation tests. Variables were identified with P-values <0.05 in univariate and multivariate analysis. Multivariate binary logistic regression analysis [odds ratio (OR) and 95% confidence interval (CI)] was performed to evaluate the predictors of MI block.

Statistical methods

All continuous variables are presented as mean ± SD or median (range) if not distributed. Continuous data were compared using Student's t-test if normally distributed or Mann–Whitney U-test if not normally distributed. Categorical data were expressed as counts and proportions and compared using the χ² test. Statistical threshold was set at P < 0.05. Statistical analysis was performed using the SPSS software (version 26.0; IBM Corporation, Somers, NY, USA).

Results

Baseline characteristics

The baseline characteristics of the patients are summarized in Table 1. A total of 118 patients were enrolled in this study between January 2018 and December 2021. The general patient characteristics were similar in all treatment arms. The mean patient age was 63.67 years. The majority of the study patients were male (73%), but the proportion of males in each group was similar. A repeat ablation procedure was performed in 46 (39.0%) of the RF group and in 72 (61.0%) of the VOM-Et-RF group. There were no significant differences in symptomatic AF episodes before inclusion in the registry between the two patient groups.

Table 1

Table 1. Baseline characteristics.

Acute conduction block at the mitral isthmus

Successful bidirectional perimitral block was achieved in 96% of patients in the VOM-Et-RF group (69 of 72) and in 76% of patients in the RF group (35 of 46) (P < 0.01) (Supplementary Figure S1). There is a significant intergroup difference in MI block rate for males (98% vs. 70%, P < 0.001), but no significant difference in female patients between the VOM-Et-RF group (91%) and RF group (86%) (Figure 3A). In terms of age, the rate of MI conduction block was significantly higher in VOM-Et-RF group (96%) than that in RF group (75%), in patients older than 60 years (Figure 3B).

Figure 3

Figure 3. Influencing factor of acute conduction block at the MI. (A) Sex; (B) Age; (C) Duration of atrial fibrillation; (D) LA diameter; (E) Diabetes; (F) Hypertension; (G) Smoke; (H) Drink. VOM-Et-RF VS RF, *P < 0.05, **P < 0.01, ***P < 0.001.

For the analysis of the duration of atrial fibrillation, the rate of block at the MI was significantly higher in the VOM-Et-RF group (100%) than RF group (78.3%) in patients with duration of AF less than 3 years. However, there was no difference in the rate of perimitral block in patients with the duration of AF more than 3 years (Figure 3C). In addition, in patients with left atrial diameter less than 55 mm, the rate of isthmus block was significantly higher in the VOM-Et-RF group (95.2%) than in the RF group (80.48%), while in patients with left atrial diameter greater than 55 mm, the rate of isthmus block was significantly higher in the VOM-Et-RF group (100%) than in the RF group (40%) (Figure 3D).

Further analysis of clinicopathological factors affecting the progression of AF showed that in non-diabetic patients, the rate of perimitral block was significantly higher in the VOM-Et-RF group (95%) than in the RF group (73%), while there was no statistical difference in the contribution of the two groups to the rate of isthmus block in diabetic patients (Figure 3E). Similarly, in non-hypertensive patients, the rate of isthmus block was dramatically higher in the VOM-Et-RF group (100%) than in the RF group (77%), but there was no significant difference in the rate of perimitral block in hypertensive patients (Figure 3F). Similarly, in non-smoking and non-drinking patients, the rate of isthmus block was remarkably higher in the VOM-Et-RF group (98% and 96%, respectively) than in the RF group (78% and 74%, respectively), while there was no significant difference in the contribution of the two groups to the rate of isthmus block in the non-smoking and non-drinking patients (Figures 3G, H).

Our further stepwise regression analysis found that only LA diameter and whether alcohol ablation was performed or not were included in the regression curve, with a significant effect on MIBB%, and all the remaining variables were removed (Table 2).

Table 2

Table 2. Analysis of the influencing factors of mitral isthmus block rate in patients.

Discussion

The main findings of the present study, indicate that VOM ethanol infusion facilitates MI conduction block. Furthermore, in the subgroup analysis, our data support that male sex, age >60 years, LA diameter <55 mm and AF duration <3 years were independently associated with the benefits of VOM-Et for AF patients.

The success rates for achieving MI block using RF range from 42% to 92% for the posterior MI line (2–8), 85%–88% for the anterior MI line (9, 10), and 98.2% for the superolateral MI line (11). Acute and long-term success may be impacted by MI thickness and duration. A growing body of research has shown that VOM is significantly associated with arrhythmias, and the main potential pathophysiological mechanisms are proximal VOM autonomic nervous system imbalance, VOM-related AT, VOM-related reentrant activities triggering AF, and focal activities perpetuating AF (12). According to preliminary clinical studies, ethanol effusion into VOM can result in a complete linear lesion along the MI and successfully block the MI (13, 14), making it a viable treatment option for peri-mitral AT. In contrast to catheter ablation alone, catheter ablation with VOM-Et enhanced the likelihood of independence from AF/AT for PeAF with one-year follow-up, according to a recent randomized, multi-center experiment (VENUS trial) (1).

The difficulties in MI ablation and the low block rate is the major consideration that preclude application of MI ablation in clinical practice. Complete MI block may be difficult to achieve due to several physical restrictions, including a thicker and longer MI (15), the heat-sink effect of blood flow in the CS and circumflex arteries, and epicardial fibers like the CS myocardial sleeve and ligament of Marshall (16–18). These factors often result in longer ablation time and higher procedural risk. In our study, we found that the size of LA and the application of VOM-Et are key factors affecting the success rate of MI Block. Atrial structural remodeling is a common phenomenon in patients with atrial fibrillation (AF), usually manifested as increased atrial volume and atrial wall fibrosis, which will increase the success rate of catheter ablation to achieve MI block. Left atrial enlargement is closely related to the severity of atrial fibrillation, especially in persistent atrial fibrillation, which increases the success rate of both PVI isolation and MI block (19).With VOM-Et, MI ablation is much facilitated. Particularly, less RF applications are required in the mid to distal part of MI including the LAA base, which has more trabeculated and creviced structures susceptible to perforation. Although VOM rupture and leaking of ethanol may occur during VOM-Et and cause pericardial effusion or pericarditis, most of these complications could be manage with medical observation and appropriate medications.

It's also critical to understand VOM-Et's own limitations. The VOM is not always available, and the accessibility rate ranges from 71.4% to 96% (13, 20, 21). The difference in techniques, limited sample size of the reports could be the potential explanations that require further research. Of special note, the annulus side of MI is not covered by the VOM-Et lesion. As previously stated and anticipated due to anatomical factors, VOM-Et mostly affects the pulmonary venous side of the mitral isthmus while sparing the annular aspect (22). For mitral isthmus ablation, epicardial ablation via the CS is frequently necessary. Epicardial ablation often targets the annular side of the mitral isthmus due to the path of the CS, paying particular attention to the CS and GCV (23).

Although VOM-Et has a great help in improving the success rate of MI Block, there are some factors that can affect its effectiveness. Our study is the first to analyze individual factors that influence the clinical outcome of VOM-Et, including the sex, age, left atrial size, and duration of atrial fibrillation, as well as hypertension, diabetes, smoking, and alcohol consumption. These factors are also important for the success rate of radiofrequency catheter ablation for atrial fibrillation. In previous reports, it has been found that the success rate of catheter ablation of MI block is affected by the thickness of the isthmus, anatomic isomerism, and connection to the epicardium. It is well known that patients with atrial fibrillation will expand the atrium because of the long duration of AF and age, which will aggravate the degree of myocardial fibrosis. These conditions can lead to a thickening of the isthmus, resulting in a low success rate of MI block for traditional catheter ablation and the need for further VOM for complementary ablation. High blood pressure, diabetes, smoking and alcohol consumption are also risk factors for exacerbating the progression of atrial fibrillation, so it is not difficult to understand their influence on the effect of VOM-Et. Sex differences have been recognized in many aspects of AF management, including epidemiology, clinical presentation, and response to treatment (24). Although current studies reported trivial sex differences in sinus rhythm maintenance after ablation (25–27), there are clues indicating sex differences in the pathophysiology of AF, such as the prevalence of non-PV triggers, atrial fibrosis, PV reconnection rate, and thickness of epicardial adipose tissue (28–31). In the present study, we further suggested a lower MI block rate in male patients who tended to benefit more from VOM-Et.

Other clinically relevant outcomes, such as the AF burden rate of repeat surgeries, showed the benefits of Marshall ethanol as well technique complications were not increased by the VOM-Et technique. The overall aggressive ablation strategy adopted in both groups was consistent with adverse outcomes. These findings further confirm the safety and efficacy of VOM-Et in improving the success rate of MI block and optimizing AF catheter ablation

Limitations

This study has several limitations. First, the study was a single-center, exploratory cross-sectional study, and the end point was immediate intraoperative MI block rate, mainly limited by the lack of follow-up and analysis of redo procedures, not possible to evaluate the long-term injury effect of VOM-Et and its contribution to the success rate of ablation of atrial fibrillation. Subgroup analysis should be interpreted with caution. Although we tried to enroll as many patients as possible, we still do not have adequate power to illustrate the effectiveness of VOM-Et in every subgroup. Therefore, a larger cohort with a longer follow-up period is warranted in the future.

Conclusion

The present study provided further evidence for the effect of VOM-Et on MI ablation in the general population and different subgroups. VOM-Et is recommended to those more refractory to radiofrequency ablation, like younger, male patients.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Ethics Committee of Taizhou Hospital in Zhejiang Province. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because Because this is a retrospective study, there is no need for participants to sign informed consent forms.

Author contributions

W-LG: Conceptualization, Investigation, Writing – original draft. Y-FL: Data curation, Methodology, Writing – original draft. TL: Data curation, Methodology, Writing – original draft. YW: Formal Analysis, Software, Writing – original draft. JY: Formal Analysis, Software, Writing – original draft. X-RL: Formal Analysis, Software, Writing – original draft. J-JJ: Data curation, Methodology, Writing – original draft. Y-FM: Formal Analysis, Software, Writing – original draft. T-HT: Editing data, Editing – original draft. S-HY: Supervision, Writing – review & editing.

Funding

This work was supported by the National Natural Science Foundation of China [82070345, 81870253], Municipal Foundation of Taizhou [22ywa12].

Acknowledgments

Mengting Lin, Xinghui Yin and Jingsong Wei are acknowledged for the statistical analyses.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2024.1253554/full#supplementary-material

References

1. Valderrábano M, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN, et al. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial. JAMA. (2020) 324(16):1620–8. doi: 10.1001/jama.2020.16195

Crossref Full Text | Google Scholar

2. Jaïs P, Hocini M, Hsu LF, Sanders P, Scavee C, Weerasooriya R, et al. Technique and results of linear ablation at the mitral isthmus. Circulation. (2004) 110(19):2996–3002. doi: 10.1161/01.CIR.0000146917.75041.58

Crossref Full Text | Google Scholar

3. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. (2015) 372(19):1812–22. doi: 10.1056/NEJMoa1408288

PubMed Abstract | Crossref Full Text | Google Scholar

4. Yokokawa M, Sundaram B, Garg A, Stojanovska J, Oral H, Morady F, et al. Impact of mitral isthmus anatomy on the likelihood of achieving linear block in patients undergoing catheter ablation of persistent atrial fibrillation. Heart Rhythm. (2011) 8(9):1404–10. doi: 10.1016/j.hrthm.2011.04.030

PubMed Abstract | Crossref Full Text | Google Scholar

5. Chae S, Oral H, Good E, Dey S, Wimmer A, Crawford T, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. J Am Coll Cardiol. (2007) 50(18):1781–7. doi: 10.1016/j.jacc.2007.07.044

PubMed Abstract | Crossref Full Text | Google Scholar

6. Choi JI, Pak HN, Park JH, Choi EJ, Kim SK, Kwak JJ, et al. Clinical significance of complete conduction block of the left lateral isthmus and its relationship with anatomical variation of the vein of Marshall in patients with nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol. (2009) 20(6):616–22. doi: 10.1111/j.1540-8167.2008.01408.x

PubMed Abstract | Crossref Full Text | Google Scholar

7. Kurotobi T, Shimada Y, Kino N, Iwakura K, Inoue K, Kimura R, et al. Local coronary flow is associated with an unsuccessful complete block line at the mitral isthmus in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. (2011) 4(6):838–43. doi: 10.1161/CIRCEP.111.964478

PubMed Abstract | Crossref Full Text | Google Scholar

8. Latcu DG, Squara F, Massaad Y, Bun SS, Saoudi N, Marchlinski FE. Electroanatomic characteristics of the mitral isthmus associated with successful mitral isthmus ablation. Europace. (2016) 18(2):274–80. doi: 10.1093/europace/euv097

PubMed Abstract | Crossref Full Text | Google Scholar

9. Lehrmann H, Jadidi AS, Minners J, Chen J, Müller-Edenborn B, Weber R, et al. Novel electrocardiographic criteria for real-time assessment of anterior mitral line block: “V1 jump” and “V1 delay”. JACC Clin Electrophysiol. (2018) 4(7):920–32. doi: 10.1016/j.jacep.2018.03.007

PubMed Abstract | Crossref Full Text | Google Scholar

10. Ammar S, Luik A, Hessling G, Bruhm A, Reents T, Semmler V, et al. Ablation of perimitral flutter: acute and long-term success of the modified anterior line. Europace. (2015) 17(3):447–52. doi: 10.1093/europace/euu297

PubMed Abstract | Crossref Full Text | Google Scholar

11. Maurer T, Metzner A, Ho SY, Wohlmuth P, Reißmann B, Heeger C, et al. Catheter ablation of the superolateral mitral isthmus line: a novel approach to reduce the need for epicardial ablation. Circ Arrhythm Electrophysiol. (2017) 10(10):e005191. doi: 10.1161/CIRCEP.117.005191

PubMed Abstract | Crossref Full Text | Google Scholar

12. He B, Wang X, Zhao F, Guo T, Po SS, Lu Z. The ligament of Marshall and arrhythmias: a review. Pacing Clin Electrophysiol. (2021) 44(5):792–9. doi: 10.1111/pace.14071

PubMed Abstract | Crossref Full Text | Google Scholar

13. Nakashima T, Pambrun T, Vlachos K, Goujeau C, André C, Krisai P, et al. Impact of vein of Marshall ethanol infusion on mitral isthmus block: efficacy and durability. Circ Arrhythm Electrophysiol. (2020) 13(12):e008884. doi: 10.1161/CIRCEP.120.008884

PubMed Abstract | Crossref Full Text | Google Scholar

14. Sang C, Lai Y, Long D, Li M, Bai R, Jiang C, et al. Ethanol infusion into the vein of Marshall for recurrent perimitral atrial tachycardia after catheter ablation for persistent atrial fibrillation. Pacing Clin Electrophysiol. (2021) 44(5):773–81. doi: 10.1111/pace.14052

PubMed Abstract | Crossref Full Text | Google Scholar

15. Báez-Escudero JL, Morales PF, Dave AS, Sasaridis CM, Kim YH, Okishige K, et al. Ethanol infusion in the vein of Marshall facilitates mitral isthmus ablation. Heart Rhythm. (2012) 9(8):1207–15. doi: 10.1016/j.hrthm.2012.03.008

Crossref Full Text | Google Scholar

16. Scherr D, Derval N, Sohal M, Pascale P, Wright M, Jadidi A, et al. Length of the mitral isthmus but not anatomical location of ablation line predicts bidirectional mitral isthmus block in patients undergoing catheter ablation of persistent atrial fibrillation: a randomized controlled trial. J Cardiovasc Electrophysiol. (2015) 26(6):629–34. doi: 10.1111/jce.12667

PubMed Abstract | Crossref Full Text | Google Scholar

17. Vlachos K, Denis A, Takigawa M, Kitamura T, Martin CA, Frontera A, et al. The role of Marshall bundle epicardial connections in atrial tachycardias after atrial fibrillation ablation. Heart Rhythm. (2019) 16(9):1341–7. doi: 10.1016/j.hrthm.2019.05.019

PubMed Abstract | Crossref Full Text | Google Scholar

18. Takigawa M, Derval N, Martin CA, Vlachos K, Denis A, Nakatani Y, et al. Mechanism of recurrence of atrial tachycardia: comparison between first versus redo procedures in a high-resolution mapping system. Circ Arrhythm Electrophysiol. (2020) 13(1):e007273. doi: 10.1161/CIRCEP.119.007273

PubMed Abstract | Crossref Full Text | Google Scholar

19. van Rosendael AR, Smit JM, El’Mahdiui M, van Rosendael PJ, Leung M, Delgado V, et al. Association between left atrial epicardial fat, left atrial volume, and the severity of atrial fibrillation. Europace. (202224(8):1223–8. doi: 10.1093/europace/euac031

PubMed Abstract | Crossref Full Text | Google Scholar

20. Holda MK, Koziej M, Holda J, Tyrak K, Piatek K, Krawczyk-Ozóg A, et al. Spatial relationship of blood vessels within the mitral isthmus line. Europace. (2018) 20(4):706–11. doi: 10.1093/europace/euw423

PubMed Abstract | Crossref Full Text | Google Scholar

21. Derval N, Duchateau J, Denis A, Ramirez FD, Mahida S, André C, et al. Marshall bundle elimination, pulmonary vein isolation, and line completion for ANatomical ablation of persistent atrial fibrillation (Marshall-PLAN): prospective, single-center study. Heart Rhythm. (2021) 18(4):529–37. doi: 10.1016/j.hrthm.2020.12.023

PubMed Abstract | Crossref Full Text | Google Scholar

22. Valderrábano M, Liu X, Sasaridis C, Sidhu J, Little S, Khoury DS. Ethanol infusion in the vein of Marshall: adjunctive effects during ablation of atrial fibrillation. Heart Rhythm. (2009) 6(11):1552–8. doi: 10.1016/j.hrthm.2009.07.036

Crossref Full Text | Google Scholar

23. Lam A, Küffer T, Hunziker L, Nozica N, Asatryan B, Franzeck F, et al. Efficacy and safety of ethanol infusion into the vein of Marshall for mitral isthmus ablation. J Cardiovasc Electrophysiol. (2021) 32(6):1610–9. doi: 10.1111/jce.15064

PubMed Abstract | Crossref Full Text | Google Scholar

24. Weberndörfer V, Beinart R, Ricciardi D, Ector J, Mahfoud M, Szeplaki G, et al. Sex differences in rate and rhythm control for atrial fibrillation. Europace. (2019) 21(5):690–7. doi: 10.1093/europace/euy295

Crossref Full Text | Google Scholar

25. Patel D, Mohanty P, Di Biase L, Sanchez JE, Shaheen MH, Burkhardt JD, et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm. (2010) 7(2):167–72. doi: 10.1016/j.hrthm.2009.10.025

PubMed Abstract | Crossref Full Text | Google Scholar

26. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. (2013) 2(2):e004549. doi: 10.1161/JAHA.112.004549

PubMed Abstract | Crossref Full Text | Google Scholar

27. Shah SV, Kruse J, Andrei AC, Li Z, Malaisrie SC, Knight BP, et al. Gender differences in outcomes after surgical ablation of atrial fibrillation. J Thorac Cardiovasc Surg. (2016) 151(2):391–8.e2. doi: 10.1016/j.jtcvs.2015.09.062

PubMed Abstract | Crossref Full Text | Google Scholar

28. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. (2000) 35(6):1669–77. doi: 10.1016/s0735-1097(00)00611-2

PubMed Abstract | Crossref Full Text | Google Scholar

29. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol. (2003) 284(1):H176–84. doi: 10.1152/ajpheart.00421.2002

PubMed Abstract | Crossref Full Text | Google Scholar

30. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. (2006) 27(2):136–49. doi: 10.1093/eurheartj/ehi645

PubMed Abstract | Crossref Full Text | Google Scholar

31. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metab Clin Exp. (2004) 53(11):1454–61. doi: 10.1016/j.metabol.2004.06.013

PubMed Abstract | Crossref Full Text | Google Scholar